To address these limitations, we used multiple clinically relevant reagents and ovarian cancer models to comprehensively investigate how ZNF217 levels impacts the different steps in ovarian cancer metastasis and therapeutic response. This evidence concerns the gene ZNF217 and ovarian carcinoma.